LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the additions of Dr. Klaus Busam, Dr. Joslyn Kirby and Dr. Justin Ko to its Scientific Advisory Board (the “Board”).
The Board provides their expertise and unique perspectives, to support DermTech’s existing innovations, development of new technologies as well as emerging technologies that may impact dermatological diseases. Their combined experience in dermatology, skin cancer, genomics and biotech innovations distinguish them as industry leaders and experts in their respective fields.
Klaus Busam, M.D., is a dual board-certified pathologist specializing in melanoma and other skin cancers holding a wealth of expertise in a variety of inflammatory reactions, including eczema and graft versus host disease. He is also an expert in cutaneous reactions to novel therapeutic agents, both targeted and immunomodulatory. Dr. Busam is currently the director of dermatology and immunohistochemistry at Memorial Sloan Kettering Cancer Center and directs the center’s joint dermatopathology training program with Cornell University. He received his medical degree at the University of Freiburg and completed Harvard Medical School’s dermatopathology fellowship prior to his residency at the Brigham’s and Women’s Hospital and Children’s Hospital at Harvard Medical School.
Justin Ko, M.D., M.B.A., serves as director and chief of medical dermatology for Stanford Health Care (SHC) while also spearheading the dermatology department’s efforts around network development, digital health, quality, safety and performance improvement and value-based care. Dr. Ko also chairs the American Academy of Dermatology’s Task Force Committee on Augmented Intelligence. In his clinical work, he focuses on early cancer detection and translational research. Dr. Ko received his bachelor’s degree from Harvard University and his combined medical and business degree from Tufts University, then completed the Harvard Dermatology Residency Training Program.
Joslyn Kirby, M.D., M.P.H., currently serves as associate professor of dermatology, director of the Dermatology Residency Program and vice chair of education at Pennsylvania State University. In her clinical and research work, she is interested in acneiform conditions including rosacea and hidradenitis suppurativa and is a board member of the Hidradenitis Suppurativa Foundation. She received her medical degree from the University of Virginia and completed her dermatology residency at the University of Pennsylvania. Dr. Kirby also completed her master’s degree in public health sciences and adult education from Pennsylvania State University.
“It is my pleasure to welcome Drs. Kirby, Busam and Ko to our Scientific Advisory Board. They join an esteemed group of minds that are partnered with us in our mission to transform dermatology,” said John Dobak, M.D., chief executive officer of DermTech. “We look forward to working with them to bring non-invasive, precision genomics to the diagnosis and treatment of dermatologic conditions.”
For more information on the DermTech Scientific Advisory Board, please visit: www.dermtech.com/about-us/scientific-advisory-board.
DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.DermTech.com.
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10-Q filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
The post DermTech Announces Three New Scientific Advisory Board Members appeared first on Fintech News.